X

Trial Profile

A Phase 1 Study of Nivolumab (BMS-936558) Plus Sunitinib, Pazopanib or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Dec 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Ipilimumab; Pazopanib; Sunitinib
Indications Renal cell carcinoma
Focus Adverse reactions
Acronyms CheckMate 016; CheckMate016
Sponsors Bristol-Myers Squibb

Most Recent Events

30 Nov 2021 Status changed from active, no longer recruiting to completed.
27 Sep 2019 Planned End Date changed from 15 Aug 2019 to 30 Jun 2021.
12 Jun 2019 Planned End Date changed from 1 Jun 2018 to 15 Aug 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com